This study is testing a new approach for people with advanced cancers linked to Human Papillomavirus (HPV), including cervical and head/neck cancers. It uses a treatment called E7 TCR-T cells, which are your own immune cells specially trained to fight cancer. Before receiving these cells, you'll get a short course of chemotherapy (cyclophosphamide and fludarabine). Then, the E7 TCR-T cells are given through a single IV infusion, followed by a medication called aldesleukin to help them work. The main goal is to see if this treatment can be given safely and effectively before your main cancer treatment (like radiation or surgery). Researchers also want to see if it shrinks tumors and improves how long people live without their cancer returning. To join, your cancer must be HPV16-positive and you need a specific genetic marker (HLA-A*02:01). The study aims to enroll 15 participants.

Study design

This is a single-arm study, meaning all 15 participants will receive the same treatment. It's a feasibility study, focused on whether the treatment can be given successfully.

What's involved

You will undergo a procedure called apheresis to collect your T cells. After treatment, you'll have follow-up visits at 3 and 6 weeks, including imaging tests to check tumor response.

Compensation

Not stated in the trial record.

Follow-up

Participants will be followed for 2 and 5 years after treatment to check for disease-free survival.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.